Kensey Nash Corp. (KNSY) announced that it has received 510 clearance for its first extracellular matrix product, Medeor Matrix, from the U.S. Food and Drug Administration. The clearance allows for the use of Medeor Matrix in general surgery for the reinforcement and repair of soft tissue, including hernia repair and plastic and reconstructive surgical applications.
Medeor Matrix is a porcine-based dermal extracellular matrix designed to act as a biologic scaffold to stimulate the deposition of organized tissues specific to an injured site.
For comments and feedback: editorial@rttnews.com